Canopy Growth (TSX:WEED; NYSE:CGC) reported net revenue of $226.3-million for the fiscal year ended March 31, 2019, an increase of 191%, compared with $77.9-million a year earlier.

ContraVir Pharmaceuticals (NASDAQ:CTRV) reported that the FDA provided positive feedback to the company’s pre-IND meeting regarding CRV431 for the treatment of non-alcoholic steatohepatitis (NASH).

BeyondSpring (NASDAQ:BYSI) will join the FTSE Russell 3000 Index when markets open on July 1, according to a preliminary list of additions. Membership in the Russell 3000 Index, which remains in place for one year...

Akari Therapeutics (NASDAQ:AKTX) reported positive data from the first part of its Phase 1/2 study of topical nomacopan in moderate to severe atopic keratoconjunctivitis (AKC).

Adamas Pharmaceuticals (NASDAQ:ADMS) reported retrospective data from pooled Phase 3 trials of GOCOVRI in Parkinson’s disease (PD) patients.

The FDA has accepted Melinta Therapeutics’ (NASDAQ:MLNT) supplemental NDA (sNDA) for BAXELDA for the treatment of community-acquired bacterial pneumonia (CABP).